Advertisement
UK markets open in 4 hours 33 minutes

  • NIKKEI 225

    38,010.47
    +48.67 (+0.13%)
     

  • HANG SENG

    16,371.17
    +119.33 (+0.73%)
     

  • CRUDE OIL

    82.76
    +0.07 (+0.08%)
     

  • GOLD FUTURES

    2,384.10
    -4.30 (-0.18%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • Bitcoin GBP

    49,363.96
    -1,847.76 (-3.61%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     

  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     
Money:

5 ways to get help with childcare costs

Childcare is eye-wateringly expensive, here are some ways to save money

What’s behind Nektar Therapeutics Stock’s Recent Price Tumble?

Kenneth Smith
Updated
What’s behind Nektar Therapeutics Stock’s Recent Price Tumble?

After a stellar rise in the past 12 months, Nektar Therapeutics (NKTR) stock fell more than 40% on June 4, which wiped out close to $6 billion of the company’s market cap. This drop was after Bristol Myers Squibb (BMY) and Nektar reported preliminary results from the currently ongoing phase one and two study for NKTR-214 in combination with Opdivo for treating patients with stage four metastatic melanoma, renal cell carcinoma, and urothelial cancers. The price of Bristol-Myers Squibb stock also witnessed selling pressure and fell almost 3% on June 4.

Continue reading